Cyclacel Continues Lung-Cancer Study
November 26th, 2007
Cyclacel Pharmaceuticals Inc. said Monday it will continue enrolling patients in its midstage program for lung-cancer treatment candidate seliciclib, despite a shortage of continuing patients.
LC KILLS MORE PEOPLE THAN BREAST,
PROSTATE, COLON, LIVER, MELANOMA,
AND KIDNEY CANCERS COMBINED.